ReviewFrontiers in immunology2026
Cholesterol in hematological malignancies: metabolism, mechanisms, and clinical implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholesterol is an amphiphilic molecule that is essential for maintaining membrane structure and integrity, serves as a precursor for steroid hormone synthesis, and plays a critical role in metabolic homeostasis and physiological function. In recent years, dysregulated cholesterol metabolism has emerged as a major focus of research in the field of hematological malignancies. A growing body of clinical evidence indicates that hypocholesterolemia is a common concomitant condition in various hematological malignancies and is closely associated with disease onset, progression, therapeutic response, and clinical outcomes. The mechanisms underlying tumor-associated hypocholesterolemia are complex and likely involve dysregulation of lipoprotein metabolism, liver dysfunction caused by systemic inflammatory responses, and abnormal cholesterol uptake and efflux by tumor cells, which collectively contribute to the exacerbation of hypocholesterolemia. In turn, this metabolic signature not only promotes tumor cell proliferation and enhances the potential for therapy resistance, but also reprograms the immune microenvironment by inducing T cell dysfunction and M2-like macrophage polarization. Emerging therapeutic strategies targeting cholesterol metabolism have shown promise in preclinical models. By providing a theoretical foundation, these strategies offer potential avenues for improving the early diagnosis and risk stratification of hematological malignancies and for developing innovative treatment regimens. In this review, we outline the biosynthesis, uptake, excretion, transformation, and regulatory networks of cholesterol; describe the specific alterations in cholesterol levels across different subtypes of hematological malignancies; elucidate the molecular mechanisms underlying hypocholesterolemia; and explore its effects on tumor cell biology and the immune microenvironment, as well as its clinical significance, with the aim of providing new perspectives for related treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.